Constrained Conditional Binding Proteins for Tumor Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies using intact monoclonal antibodies face challenges such as poor biodistribution, low potency, and 'on target/off tumor' effects due to their large size and rapid clearance, leading to inadequate tumor penetration and toxic side effects on healthy cells.
Innovation Solution
Development of a fusion protein comprising specific domain structures that are selectively activated by tumor proteases, including a constrained Fv domain and a pseudo Fv domain, which remain inactive until cleaved, allowing for targeted binding to CD3 and tumor antigens, thereby enhancing tumor specificity and reducing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If intact monoclonal antibodies are used for cancer therapy, then binding specificity and affinity for tumor-associated antigens are improved, but tumor penetration is worsened due to large size and poor biodistribution
Solution Approach 1:
The patent divides the intact monoclonal antibody into smaller functional fragments (Fab fragments, scFv domains, and single-domain antibodies) that can penetrate tumors more effectively while retaining antigen-binding capability. The constrained Fv domain and pseudo Fv domain are designed as separate modules that can be reconfigured upon proteolytic cleavage.
Solution Approach 2:
The antibody construct is designed to dynamically change its structure and functionality in response to the tumor microenvironment. The constrained Fv domain remains inactive until cleaved by tumor-associated proteases, at which point it transforms into an active binding configuration. This dynamic activation allows the molecule to adapt its properties based on location.
2Measurement precision
If intact monoclonal antibodies are used, then binding affinity is improved, but persistence in blood pool increases leading to reduced clearance
Solution Approach 1:
The patent uses smaller antibody fragments (Fab fragments with molecular weight ~50 kDa, scFv domains ~25 kDa) instead of intact IgG (~150 kDa). These smaller fragments exhibit rapid tumor localization and are removed more quickly from the bloodstream, reducing persistent exposure to healthy tissues.
Solution Approach 2:
The patent alters the molecular size and structural parameters of the antibody construct to optimize pharmacokinetic properties. By using constrained Fv domains with specific linker lengths and compositions, the molecule achieves both rapid tumor penetration and controlled clearance rates.
3Length of moving object
If smaller antibody fragments are used to improve tumor penetration, then biodistribution is improved, but on-target/off-tumor effects increase causing toxicity
Solution Approach 1:
The Fv domain is designed in a constrained, inactive state during circulation that prevents binding to CD3 and immune cell engagement. The constraint mechanism (using linkers and domain orientation) ensures the molecule cannot exert its cytotoxic effect until it reaches the tumor microenvironment where proteolytic cleavage activates it.
Solution Approach 2:
The patent introduces tumor-associated proteases as intermediary activators. These proteases are overexpressed in the tumor microenvironment and specifically cleave the constrained Fv domain to activate it. This intermediary mechanism ensures that activation occurs preferentially at the tumor site rather than systemically.
4Measurement precision
If intact antibodies are used, then binding specificity is improved, but accumulation is restricted to peripheral tumor regions due to increased interstitial tissue pressure
Solution Approach 1:
The patent employs smaller antibody fragments (scFv, Fab) that can physically navigate through the dense tumor stroma and reach central regions. The reduced size allows these fragments to overcome the physical barriers (increased interstitial pressure, dense extracellular matrix) that block larger intact antibodies from penetrating deep into the tumor.
Solution Approach 2:
The patent modifies the molecular size parameter of the antibody construct to optimize tissue penetration. By using constrained Fv domains with molecular weights significantly lower than intact IgG, the molecule achieves deeper tumor penetration while maintaining sufficient binding affinity through optimized CDR regions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion protein achieves deeper tumor penetration and selective activation within the tumor microenvironment, reducing toxicity and improving therapeutic efficacy by ensuring targeted engagement of immune cells to tumor cells while sparing healthy tissues.
Implementation Method 1
the first variable heavy domain and the first variable light domain of the constrained Fv domain are capable of binding human CD3 but the constrained pseudo Fv domain does not bind CD3; the first variable heavy domain and the first pseudo variable light domain intramolecularly associate to form an inactive Fv; and the first variable light domain and the first pseudo variable heavy domain intramolecularly associate to form an inactive Fv
Implementation Method 2
The present invention is related to novel constructs that are selectively activated in the presence of tumor proteases
Data Source
AI summary
The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.